Sanofi Regeneron Investor Agreement

Dec 16th, 2020 | By | Category: Uncategorized

Regeneron Pharmaceuticals, Inc.Charles Poole, 1-914-345-7640Vice President, Investor Relationscharles.poole@regeneron.comorMedia RelationsLaura Lindsay, 1-914-345-7800laura.lindsay@regeneron.comorMedia RelationsKimberly Chen, Regeneron Forward-Looking StatementThis press release contains forward-looking statements that involve risks and uncertainties regarding Regeneron`s future events and future performance, and actual events or results may differ materially from such forward-looking statements. Words such as “anticipate,” “expect,” “plan,” “believe,” “seek,” “appreciate,” variations in such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain such identifying words. These statements relate, among other things, to the nature, timing and possible therapeutic and successful applications of Regeneron products, product candidates and current or scheduled research and clinical programs, including, but not only the EYLEA® (Aflibercept) injection; unforeseen safety issues resulting from the administration of products and product candidates in patients, including complications or serious adverse events related to the use of Regeneron candidates in clinical trials; the likelihood and date of possible marketing authorization and marketing of Regeneron`s late-stage products and new indications for marketed products; regulatory obligations and ongoing oversight of Regeneron`s research and clinical programs and activities; regulatory and administrative findings that may delay or limit Regeneron`s ability to develop or market Regeneron`s products and products; Competing candidates for products and products that may be superior to Regeneron`s products and candidates; Uncertainty about market acceptance and the commercial success of Regeneron`s products and products; Regeneron`s ability to produce and manage supply chains for multiple products and candidates; third-party payers, including Medicare and Medicaid, are covered and reimbursed; Unforeseen expenses The costs of designing, manufacturing and selling products; Regeneron`s ability to meet any of its sales or other financial forecasts or guidelines, and changes in the assumptions underlying these projections or guidelines; the potential for termination or termination of licensing or collaboration agreements, including Regeneron`s agreements with Sanofi and Bayer HealthCare, without further product success; risks related to the intellectual property of third parties and ongoing or future litigation related to third parties. A more detailed description of these and other significant risks can be found in Regeneron`s notifications to the United States Securities and Exchange Commission, including Form 10-K for the year past December 31, 2012 and Form 10-Q for the quarterly period, which ended September 30, 2013. Readers are cautioned not to rely on Regeneron`s forward-looking statements. Regeneron undertakes not to publicly update forward-looking statements, including, but is not limited to financial projections or guidance, whether as a result of new information, future events or other events. Sanofi-aventis will hold a conference call today, November 29, 2007, at 12:00 p.m. CET to discuss the new cooperation. It will also be available in edge-down mode on the sanofi-aventis website:

Comments are closed.